Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Still a Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up before the market opened on Tuesday . The stock had previously closed at $31.16, but opened at $33.79. Nanobiotix shares last traded at $33.3740, with a volume of 8,157 shares traded.

Wall Street Analyst Weigh In

NBTX has been the subject of a number of analyst reports. UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Guggenheim boosted their price target on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Nanobiotix Price Performance

The firm’s 50-day simple moving average is $31.69 and its 200 day simple moving average is $25.25.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million for the quarter. On average, equities analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current year.

Hedge Funds Weigh In On Nanobiotix

Large investors have recently made changes to their positions in the business. Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP bought a new position in shares of Nanobiotix during the 4th quarter valued at about $220,000. Royal Bank of Canada boosted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Optiver Holding B.V. purchased a new stake in shares of Nanobiotix during the third quarter valued at $101,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.